Harmonizing Strategic Partnerships & Patient-Centric Biomarker & Drug-Diagnostic Strategies with Regulatory Expectations to Streamline Access to Safer, More Efficacious Precision Therapeutics
Driven by advancements in genomic profiling, omics, and AI technologies, the biomarkers and diagnostics field continues to surge, with Roche and AstraZeneca’s world-first digital pathology CDx approval in April taking the number of approved CDx tests to a record high of 188.
We are now witnessing a need for new, stronger co-development partnerships to validate novel biomarkers, navigate global in vitro diagnostic regulation, and harmonize commercialization; which will in turn accelerate adoption of these drug-diagnostics across diverse therapeutic areas and markets.
Returning for its 15th anniversary this September, the World Clinical Biomarkers & Companion Diagnostics Summit will unite 600+ industry leaders across biopharma, CDx developers, testing labs, regulators, and payers to advance clinical biomarker strategies and accelerate drug-diagnostics to market for improved patient diagnosis, stratification, and monitoring.
Join us in celebrating 15 years of progress and be a part of the conversations and collaborations to define the next 15.
Attending Companies Include







